SANTARUS INC 4
4 · SANTARUS INC · Filed Jan 6, 2014
Insider Transaction Report
Form 4
SANTARUS INCSNTS
SNYDER KENT
Director
Transactions
- Disposition from Tender
Common Stock
2014-01-02$32.00/sh−1,000$32,000→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$10.07/sh−32,000$322,240→ 0 totalExercise: $21.93Exp: 2023-06-11→ Common Stock (32,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$29.98/sh−26,500$794,470→ 0 totalExercise: $2.02Exp: 2018-06-12→ Common Stock (26,500 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$25.27/sh−30,000$758,100→ 0 totalExercise: $6.73Exp: 2016-06-07→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
2014-01-02$29.00/sh−15,000$435,000→ 0 totalExercise: $3.00Exp: 2015-06-09→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]By the Snyder Family Trust dated July 17, 2000.
- [F2]Represents options to purchase common stock of Santarus, Inc. ("Santarus"). In connection with the merger (the "Merger") of Willow Acquisition Sub Corporation ("Merger Sub") with and into Santarus pursuant to the Agreement and Plan of Merger, dated as of November 7, 2013 (the "Merger Agreement"), between Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Merger Sub and Santarus, such options (i) became fully vested and exercisable prior to the effective time of the Merger and (ii) to the extent not exercised on or prior to the effective time, were cancelled and converted into the right to receive a cash payment in the amount by which the per share purchase price of $32.00 exceeded the exercise price of the option as of the effective time of the Merger.